Cargando…

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure

AIMS: Randomized data on the efficacy/safety of cardiac resynchronization therapy with vs. without defibrillator (CRT-D,-P) in heart failure with reduced ejection fraction (HFrEF) are scarce. We aimed to evaluate survival associated with use of CRT-D vs. CRT-P in a contemporary cohort with HFrEF. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schrage, Benedikt, Lund, Lars H, Melin, Michael, Benson, Lina, Uijl, Alicia, Dahlström, Ulf, Braunschweig, Frieder, Linde, Cecilia, Savarese, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Cinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742627/ https://www.ncbi.nlm.nih.gov/pubmed/34486653 http://dx.doi.org/10.1093/europace/euab233

Ejemplares similares

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality
por: Schrage, Benedikt, et al.
Publicado: (2022)

Classification of sinus rhythm single potential morphology in patients with mitral valve disease
por: van Schie, Mathijs S, et al.
Publicado: (2020)

Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure
por: Lindberg, Felix, et al.
Publicado: (2022)

Comparison of Short-Course and Conventional Antimicrobial Duration in Mild and Moderate Complicated Intra-Abdominal Infections: A randomised controlled trial
por: Vinodhini, P., et al.
Publicado: (2023)

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

What determines who gets cardiac resynchronization therapy in europe?
por: Gatti, P, et al.
Publicado: (2023)

Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Remote monitoring of implantable cardioverter-defibrillators and resynchronization devices to improve patient outcomes: dead end or way ahead?
por: Braunschweig, Frieder, et al.
Publicado: (2019)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

A registry‐based algorithm to predict ejection fraction in patients with heart failure
por: Uijl, Alicia, et al.
Publicado: (2020)

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries
por: Batra, Gorav, et al.
Publicado: (2022)

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
por: Savarese, Gianluigi, et al.
Publicado: (2020)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Clinical outcomes of cardiac resynchronization therapy with and without a defibrillator in elderly patients with heart failure
por: Christie, Simon, et al.
Publicado: (2018)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
por: Janse, Roemer J., et al.
Publicado: (2022)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Sex‐Specific Differences in Survival and Heart Failure Hospitalization After Cardiac Resynchronization Therapy With or Without Defibrillation
por: Leyva, Francisco, et al.
Publicado: (2019)

Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis
por: Savarese, Gianluigi, et al.
Publicado: (2020)

Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
por: Shahim, Angiza, et al.
Publicado: (2023)

Renal function and the long‐term clinical outcomes of cardiac resynchronization therapy with or without defibrillation
por: Leyva, Francisco, et al.
Publicado: (2019)

Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project
por: Hadwiger, Moritz, et al.
Publicado: (2022)

An updated meta-analysis of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy
por: Liu, Fuwei, et al.
Publicado: (2023)

Ventricular arrhythmia events in heart failure patients with cardiac resynchronization therapy with or without a defibrillator for primary prevention
por: Nakamura, Toshihiro, et al.
Publicado: (2022)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

Dyssynchrony and resynchronization in heart failure—effects on regional and global gene expression in a murine pacemaker model
por: Ståhlberg, Marcus, et al.
Publicado: (2023)

Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy
por: Leyva, Francisco, et al.
Publicado: (2018)

Arrhythmic and mortality outcomes in patients with dilated cardiomyopathy receiving cardiac resynchronization therapy without defibrillator
por: Samy, Mohammed, et al.
Publicado: (2023)

Changing health related quality of life and outcomes in heart failure by age, sex and subtype
por: Lawson, Claire A., et al.
Publicado: (2023)

Manual vs. automatic capture management in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators
por: Murgatroyd, Francis D., et al.
Publicado: (2010)

Age-stratified comparison of prognosis in cardiac resynchronization therapy with or without prophylactic defibrillator for nonischemic cardiomyopathy—a nationwide cohort study
por: Farouq, Maiwand, et al.
Publicado: (2023)

Cardiac resynchronization therapy defibrillators in patients with permanent atrial fibrillation
por: Rapacciuolo, Antonio, et al.
Publicado: (2021)

Cardiac Resynchronization Therapy Defibrillator Treatment in a Child with Heart Failure and Ventricular Arrhythmia
por: Kim, Hak Ju, et al.
Publicado: (2016)

Left-bundle branch block, an alert for cardiac resynchronization therapy
por: Gatti, P, et al.
Publicado: (2023)

Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure
por: Szummer, Karolina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rsjhi4k8jlvu2in0r1hco28dfm